SHERI MCAFEE-GARNER: Open Payments
NPI 1639413867 · MILLSBORO, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$955 in 35 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $682 · 2025 $955
Food & beverage: $955
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $361 |
| ABBVIE INC. | 19 | $353 |
| Gilead Sciences, Inc. | 1 | $125 |
| Lundbeck LLC | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Indivior Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
Products named: VRAYLAR, REXULTI, Epclusa, ABILIFY MAINTENA, ABILIFY ASIMTUFII, HETLIOZ, INVEGA SUSTENNA, SUBLOCADE.
Industry payments across DE — which companies pay providers there.
